Abpro Holdings, Inc.

Abpro Holdings, Inc. (Nasdaq: ACAB) is a blank check company formed to pursue a business combination in the life sciences and biotechnology sector. Affiliated with Abpro Bio, Inc., a clinical-stage antibody therapeutics developer, the SPAC completed its initial public offering in 2021 and remained active in its target search as of its Form 10-Q filing with the Securities and Exchange Commission in November 2022. As a healthcare-focused vehicle, ACAB reflected the sustained investor appetite for biopharmaceutical deal flow that characterized the broader SPAC formation cycle of 2021. For full filing history, sponsor profiles, and current deal status on ACAB, sign up for complete data at SpacDesk.